Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 5Rhabdomyosarcoma 4Osteosarcoma 3Carcinoma, Non-Small-Cell Lung 3Sarcoma, Synovial 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Pinealoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1

Interventions

cabozantinib 3vandetanib 2sargramostim 2Trastuzumab 2Everolimus 2tipifarnib 1tanespimycin 1pembrolizumab 1pazopanib 1cixutumumab 1aldesleukin 1Vorinostat 1Tamoxifen 1Sunitinib 1Specimen Handling 1Sorafenib 1Salts 1Radiotherapy 1Pharmacogenomic Testing 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Interleukin-12 Subunit p35 1Interleukin-12 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gefitinib 1Doxorubicin 1Cisplatin 1Bortezomib 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Medullary × cixutumumab × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡